Cogentis Therapeutics is the Winner of the New Company/Technology Pitch Competition at the CNS Diseases Summit

Satish Medicetty | September 21st, 2017

We were truly excited to conduct our inaugural new company/technology pitch competition at last week’s CNS diseases summit in Boston, MA. Four finalists, Orion Biosciences, Cogentis Therapeutics, Neurolucent and Acelot, participated in this fast-paced pitch session that included rating from judges as well as audience. The judges, Christine Brennan from MRL Ventures, Barbara Tate from SV Life Sciences and Ole Isacson from Harvard Medical School, rated the presentations based on the following categories, (1) Technology description (2) Market need (3) Proof-of-concept data (4) Commercialization potential and (5) Presentation skills. Audience had an opportunity to rate all the companies through a web portal. And the final result was………Cogentis Therapeutics was the winner of the “Most Promising Technology” award and a $5000 check. Kent Werner was ecstatic and so was I to present the trophy and the check to Cogentis. I also would like to congratulate Joshua Sestak from Orion Biosciences, Bill Kohl Brenner from Neurolucent and Ambuj Singh from Acelot, for being the finalists and participating in this competition.

Cogentis Winner

GTCbio’s goal is to provide a platform for new companies/technologies that can eventually benefit the patients. We will continue to provide visibility to all finalists and we will work with Cogentis to continue to update everyone about their progress. As part of our Start-Up Corner initiative, I welcome all life-science startups and new technologies to reach out to us to discuss more on how we can help.